CLLS

Cellectis
CLLS
Market cap $191M

1.91 USD

+0.01

0.53%

At close Oct 17, 4:00 PM EDT

1 day

0.53%

5 days

-3.05%

1 month

-18.38%

3 months

-9.05%

6 months

-22.36%

Year to date

-37.79%

1 year

41.48%

5 years

-81.90%

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Employees: 216

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0.3% less ownership

Funds ownership: 13.85% [Q1] → 13.56% (-0.3%) [Q2]

13% less funds holding

Funds holding: 31 [Q1] → 27 (-4) [Q2]

31% less capital invested

Capital invested by funds: $26.3M [Q1] → $18.3M (-$8.06M) [Q2]

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

76% less call options, than puts

Call options by funds: $8K | Put options by funds: $33K

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CLLS.

See Analyst Rankings

Financial journalist opinion

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a scientific article in Science Advances suggesting that TALEN®-edited MUC1 CAR T-cells could be a potential treatment option for advance-stage triple negative breast cancer (TNBC) patients with limited therapeutic options.

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Cellectis S.A. leverages its UCART platform and TALEN gene-editing technology to develop innovative, off-the-shelf CAR-T therapies for cancer treatment. UCART22, a key candidate in Cellectis's pipeline, shows promising efficacy and safety for ALL with CLLS52. The company's promising pipeline also includes UCART20x22 for NHL with a favorable safety profile.

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Molecular Therapy demonstrating TALEN®-mediated gene editing capabilities for design of SMART DUAL CAR T-cells, which efficiently target immunotherapy recalcitrant solid tumors while mitigating potential safety risks.

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately.

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Cellectis Provides Financial Results for the Second Quarter 2024

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024.

Cellectis Provides Financial Results for the Second Quarter 2024

FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Cellectis' CLLS52 (alemtuzumab), an Investigational Medicinal Product (IMP) used as part of the lymphodepletion regimen associated with UCART22, evaluated in the BALLI-01 clinical trial in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL).

FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug (ODD) and Rare Pediatric Disease Designation (RPDD) Status to UCART22 product candidate for the treatment of Acute Lymphoblastic Leukemia (ALL).

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Zacks Investment Research

Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)

Cellectis (CLLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing.

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

See News Rankings

Charts implemented using Lightweight Charts™